On June 25, the 2026 PDI Pharmaceutical R&D & Innovation Conference and Launch Ceremony of Top 100 Pharmaceutical R&D Rankings (the 11th PDI Conference) grandly kicked off in Chengdu, Sichuan Province, where the 2026 China Pharmaceutical R&D Strength Ranking Series was officially released. Relying on its steadily growing comprehensive strength, Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) was once again included in the Top 20 Chinese Pharmaceutical CDMO Enterprises list with an improved ranking.
Learn More
The 24th CPHI China 2026 was held at Shanghai New International Expo Centre from June 16 to 18. Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical), alongside its parent company Nanjing Vcare PharmaTech Co.,Ltd. (Nanjing Vcare), showcased its full portfolio including innovative drug CDMO services, high-end APIs and advanced pharmaceutical intermediates, presenting integrated full-industry-chain solutions to pharmaceutical enterprises at home and abThe 24th CPHI China 2026 was held at Shanghai New International Expo Centre from June 16 to 18. Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical), alongside its parent company Nanjing Vcare PharmaTech Co.,Ltd. (Nanjing Vcare), showcased its full portfolio including innovative drug CDMO services, high-end APIs and advanced pharmaceutical intermediates, presenting integrated full-industry-chain solutions to pharmaceutical enterprises at home and abroad.road.
Learn More
Recently, Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) received the official approval notice for the marketing application of Eratrectinib API issued by the NMPA. This approval entitles Tianshu Pharmaceutical to conduct commercial manufacturing and market supply of this novel anti-tumor drug’s API. It further enriches the company’s high-end API product portfolio and fuels the independent and controllable development of the domestic innovative drug industrial chain.
Learn MoreOn May 2, Lu Yuqing, Secretary of the Party Leadership Group and Director of Hubei Provincial Development and Reform Commission, conducted a special research tour in Yicheng City. The tour focused on studying and implementing a correct view on performance, stabilizing economic growth in the second quarter, expanding effective investment, improving the quality and efficiency of the service industry, and advancing high-quality project development. Meng Yanqing, Member of the Standing Committee of Xiangyang Municipal Party Committee and Executive Vice Mayor, and Wu Yiquan, Secretary of Yicheng Municipal Party Committee, accompanied the inspection.
Learn MoreRecently, the Deputy Secretary of the Yicheng Municipal Party Committee and Mayor of Yicheng City, Hubei Province, led a special inspection delegation to conduct an on-site inspection and guidance at Vcare PharmaTech, the headquarters of Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical). Focusing on the Phase II project construction and long-term future development plans of Tianshu Pharmaceutical, this inspection aims to gain an in-depth understanding of the enterprise’s development momentum, precisely meet the enterprise’s demands, deepen government-enterprise cooperation, and jointly promote the high-quality development of the pharmaceutical and health industry in Yicheng.
Learn MoreRecently, the Dapagliflozin Propylene Glycol Monohydrate API, independently developed and manufactured by Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical), has officially obtained the acceptance notice for the CEP to the European Pharmacopoeia issued by the EDQM. This milestone marks a crucial step forward for Tianshu Pharmaceutical in API R&D, registration, quality management and international compliance capabilities, further enhancing the company's competitiveness in the high-end API sector.
Learn More